LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Accueil・Liste d'Actions・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Fermé

15.14 -0.2

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.76

Max

15.26

Chiffres clés
By Trading Economics
Revenu	-6.4M -20M
Ventes	-807K 71M
BPA	-0.13
Marge bénéficiaire	-28.24
Employés	624
EBITDA	-7.9M -14M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+33.14% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-95M 2.2B
Ouverture précédente	15.34
Clôture précédente	15.14

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

1 juin 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 juin 2026, 23:38 UTC

Acquisitions, Fusions, Rachats

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 juin 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 juin 2026, 22:08 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 juin 2026, 22:01 UTC

Acquisitions, Fusions, Rachats

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 juin 2026, 21:55 UTC

Acquisitions, Fusions, Rachats

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 juin 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 juin 2026, 21:22 UTC

Market Talk

Acquisitions, Fusions, Rachats

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 juin 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1 juin 2026, 20:46 UTC

Acquisitions, Fusions, Rachats

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 juin 2026, 20:22 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 juin 2026, 20:21 UTC

Acquisitions, Fusions, Rachats

Array Digital Infrastructure Declares $11 Special Div

1 juin 2026, 20:20 UTC

Acquisitions, Fusions, Rachats

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 juin 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 juin 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 juin 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 juin 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 juin 2026, 18:54 UTC

Acquisitions, Fusions, Rachats

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 juin 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 juin 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1 juin 2026, 18:00 UTC

Acquisitions, Fusions, Rachats

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 juin 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 juin 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 juin 2026, 17:10 UTC

Market Talk

Acquisitions, Fusions, Rachats

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

33.14% hausse

Prévisions sur 12 Mois

Moyen 20.17 USD 33.14%

Haut 22 USD

Bas 18 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.